111 results
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
. Benefits and expenses Benefits To align to market practice and help enable Board members fulfil their duties. The Company provides administrative support … across the Company. Benefits Competitive benefits are provided to attract and retain executives, contribute towards retirement planning and provide
6-K
EX-99.3
GLPG
Galapagos NV
11 Apr 22
Current report (foreign)
5:14pm
and governance structure and expected resulting benefits, and statements relating to the timing or likelihood of pricing and reimbursement interactions … not be able to realize the expected benefits from the proposed one-tier board structure, the risk that we may not be able to realize the expected
6-K
EX-99.1
GLPG
Galapagos NV
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
Continuing filgotinib 200mg among induction non-responders at week 10 resulted in clinical benefits for ulcerative colitis (UC) patients in the long-term … , for the treatment of patients with moderately to severely active UC. These analyses showed clinical benefits of continued dosing with filgotinib 200mg, an oral once
6-K
EX-99.1
GLPG
Galapagos NV
27 Apr 22
Galapagos announces appointment of Dr. Paul Stoffels as Chairman of the board
6:00am
to realize the expected benefits from the proposed one-tier board structure and the risk that we may not be able to realize the expected benefits from
6-K
EX-99.1
GLPG
Galapagos NV
23 Dec 22
Galapagos announces changes to Executive Committee
6:05am
statements regarding the announced leadership transition and Executive Committee appointments, benefits the company expects to realize from new … on them. These risks, uncertainties and other factors include, without limitation, the risk that we may not be able to realize the expected benefits from
6-K
EX-99.1
8xqhe
24 Mar 22
Galapagos publishes 2021 annual report and announces Biographies of proposed new board members
8:13pm
6-K
EX-99.1
jc2qmc01irrslu jlf
23 Jun 22
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
11:21am
6-K
EX-99.1
yflv1x h9fy0
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
pm8ke1agyu271ehu 3z
16 May 24
Current report (foreign)
8:11am
6-K
EX-99.1
fp6d89jr17r2l
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.1
boe ddm8krjp9ipzm
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
1c372
29 Aug 19
Gilead and Galapagos Complete Closing of Their Transformative Research and Development Collaboration
4:44pm
20-F
0xf6i4lkw 9tcc
25 Mar 16
Annual report (foreign)
12:00am
6-K
EX-99.2
dp3n r3ry
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
dpdcz828 bmk9341pggm
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
DRS
EX-10
me6k6 ey2s9l
6 Feb 15
Draft registration statement
12:00am
6-K
EX-99.1
3u7n63vf6f5i
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
DRS
EX-10
kvdu2dvfh 8tyumt62tq
6 Feb 15
Draft registration statement
12:00am